Navigation Links
Bio-AMD, Inc.; DSR Commercial Refinement, Prospective Patent Applications

LONDON, Dec. 21, 2011 /PRNewswire/ -- Bio-AMD, Inc. ("Bio-AMD" or the "Company) (OTCBB: BIAD) today announces an update on progress on a Digital Strip Reader ("DSR"), one of the three core Point Of Care ("POC") diagnostic device technologies owned by its 63% owned subsidiary, Bio-AMD Limited.

The Company believes that DSR can be applied to semi-quantitatively read lateral flow test strips for multiple diagnostics, particularly in established pregnancy and women's wellbeing tests market, where there is a shift toward digital devices.  Bio-AMD Limited is developing strategic relationships in the cardiovascular, cholesterol and infectious diseases markets where there are clear commercial and medical advantages to quick, accurate and affordable diagnosis results, without the need for laboratory intervention.

In response to discussions with potential commercial partners Bio-AMD Limited has further developed its single test DSR device to include a proprietary sensor array element. This improves sensor sensitivity, reliability and output matching. It also offers a 70% cost of manufacture saving and a wider universe of potential component suppliers, compared to previous designs. Bio-AMD Limited expects to make a patent application for this technology.

Bio-AMD Limited has also further refined its multi test DSR technology to address specific commercial needs.  This now offers an up to 40% cost of manufacture saving and is more environmentally friendly, with very low power requirements, compared to previous designs.  An increased number of common components in the multi test device also allow further economies of scale across multiple DSR applications. This is believed to precisely address the needs of key commercial players seeking to licence this type of technology. Bio-AMD Limited intends to make a further patent application for its multi-test cartridge/reader mechanism.

The Company is confident that Bio-AMD Limited has every prospect of entering into commercial development and licencing agreements(s) for DSR in 2012. Manufacturers and distributors not yet in discussion with Bio-AMD Limited may contact the company at

About Bio-AMD, Inc.

Bio-AMD has two majority owned UK subsidiaries: Bio-AMD Limited, a technology developer for medical diagnostic devices; and the WDX Organisation Ltd, the owner of the Wocu™, a global currency data reference source for application in financial markets. (

To find out more about Bio-AMD (OTCBB: BIAD), visit our websites at

Forward-Looking Statements

Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties.  Forward-looking statements can often be identified by words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import.  Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management.  Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company.  Readers are cautioned not to place undue reliance on such forward-looking statements.  Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2010 filed on March 23, 2011.  Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.


Bio-AMD, Inc.


Tom Barr, CEO


+44 (0)8445 861 910

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Raises Target Price From $4.40 to $6.50
2. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
3. VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent
4. Ikaria(R) Strengthens Commercial Operations and Human Resources Leadership
5. Nucletron Announces Market Release of First Commercially Available Software to Review and Share Dicom-Based Treatment Plans for Radiotherapy
6. CMS, Inc., an Elekta Company, Announces Commercial Availability of Focal4D(TM)
7. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
8. NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
9. Samaritan Partners Forgetful Rat Model to Taconic to Commercialize
10. POET Receives Additional $76 Million in Federal Funding For Commercialization of Cellulosic Ethanol
11. Oncolytics Biotech Inc. Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R) to Commercial Scale
Post Your Comments:
(Date:11/24/2015)... 24, 2015 Cepheid (NASDAQ: CPHD ) ... the following conference, and invited investors to participate via ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ... New York, NY      Tuesday, December 1, ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) ... of the Toronto Stock Exchange, confirms that as of ... corporate developments that would cause the recent movements in ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged ...
(Date:11/24/2015)... November 24, 2015 SHPG ) announced today ... the Piper Jaffray 27 th Annual Healthcare Conference in ... 2015, at 8:30 a.m. EST (1:30 p.m. GMT). --> ... Officer, will participate in the Piper Jaffray 27 th Annual ... on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. ...
(Date:11/24/2015)... Urdorf, Switzerland (PRWEB) , ... November 24, 2015 ... ... the plant and the environment are paramount. Insertion points for in-line sensors can ... TOLEDO has developed the InTrac 781/784 series of retractable sensor housings , ...
Breaking Biology Technology:
(Date:11/18/2015)... new scientific discoveries deepen our understanding of how cancer ... challenges in better using that knowledge to guide treatment ... children continue to survive pediatric cancer, that counseling may ... John M. Maris, M.D ., a pediatric oncologist ... --> John M. Maris, M.D ., ...
(Date:11/17/2015)... EASTON, Mass. , Nov. 17, 2015 ... a leader in the development and sale of broadly ... the worldwide life sciences industry, today announced it has ... of its $5 million Private Placement (the "Offering"), increasing ... to $4,025,000.  One or more additional closings are expected ...
(Date:11/11/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology company ... to announce that it will be a Sponsor of the ... be held November 17-19 in Hamburg , ... iMedNet , MedNet,s easy-to-use, proven and affordable ... been able to deliver time and cost savings of up ...
Breaking Biology News(10 mins):